my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
SIRION Biotech is Europe's leading commercial supplier of viral vectors used for genetic cell modelling, gene target validation and gene therapy- and vaccination studies. Since its foundation in 2007, SIRION’s mission has been to change the paradigm for viral vector supplies. It has the ability to more
CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body t more
BioNTech (Biopharmaceutical New Technologies) AG is a "spin-off"-company of the Johannes Gutenberg University located in Mainz, Germany. The company, which is financed by AT Impf GmbH (a wholly owned company of Dr. Andreas & Dr. Thomas Strüngmann) and MIG Fonds, owns four subsidiaries, Ribological, more
The European Patent Office (EPO) honoured Hungarian-American researcher Katalin Karikó with the European Inventor Award 2022 in the category "Lifetime achievement", for her seminal work in developing modified messenger RNA (mRNA) for vaccines and medical therapies. For more than four decades, Karikó more
The European Patent Office (EPO) distinguished Swiss biotechnologist Madiha Derouazi and French immunologist Elodie Belnoue with the European Inventor Award 2022 in the "SME" category. The pair have developed a vaccine assembly platform called KISIMA to produce vaccines for treating different types more
Valneva SE and Pfizer Inc. announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of more
Pathogens are continuously emerging and evolving. Addressing the threat of new and potentially life-threatening pathogens requires deep understanding more
By now, we’re all familiar with the image of coronavirus. The spikey blob peppers news websites, looms behind reporters during bulletins and frequently punctuates your Twitter doom-scrolling. More recently, the news accompanying this image has taken a positive turn, with promising results from the C more
The recent measles outbreak in the US has once again provoked discussion over vaccinations, and why some parents choose not to vaccinate their children despite the benefits of doing so. Whilst not the only factor, part of the blame lies with misinformation about the chemical composition of vaccines more
Viruses, Vol. 10, Pages 347: Protection against Virulent Infectious Bronchitis Virus Challenge Conferred by a Recombinant Baculovirus Co-Expressing S1 and N Proteins Viruses doi: 10.3390/v10070347 Authors: Yuan Yuan Zhi-Peng Zhang Yi-Ning He Wen-Sheng Fan Zhi-Hua Dong Li-Hua Zhang more
Abstract Trypanosoma brucei is a pathogenic protozoa that causes chronic Human African Trypanosomiasis and African Animal Trypanosomiasis. The pathogenic parasite is transmitted to humans by the tsetse fly, Glossina m. morsitans. Trypanosomiasis control strategies have targeted either the tsetse ve more
Viruses, Vol. 10, Pages 325: A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase Viruses doi: 10.3390/v10060325 Authors: Ping Li Qinghua Cui Lin Wang Xiujuan Zhao Yingying Zhang Balaji Manicassamy Yong Yang more
Timeline of vaccines This is a timeline of the development of prophylactic human vaccine s. Early vaccines may be listed by the first year of development or testing, but later entries usually show the year the vaccine finished trials and became ... more
Watchlist
This is where you can add this topic to your personal favourites
© 1997-2022 LUMITOS AG, All rights reserved
Topics
